NASDAQ:CUE

Cue Biopharma (CUE) Stock Forecast, Price & News

$2.41

+0.05 (+2.12%)

(As of 01:57 PM ET)

Compare

Today's Range: $2.37
▼
$2.56
50-Day Range: $2.23
▼
$4.50
52-Week Range: $2.18
▼
$5.12

Volume: 247,628 shs
Average Volume: 293,919 shs
Market Capitalization: $108.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.33

Cue Biopharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 247.2% Upside
$8.33 Price Target
Short Interest: Bearish
5.49% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.58
Upright™ Environmental Score
News Sentiment: 0.08
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$19,620 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.22) to ($1.19) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

339th out of 963 stocks

Pharmaceutical Preparations Industry

144th out of 451 stocks

3.5

Analyst's Opinion

Consensus Rating
Cue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.33, Cue Biopharma has a forecasted upside of 247.2% from its current price of $2.40.
Amount of Analyst Coverage
Cue Biopharma has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.49% of the outstanding shares of Cue Biopharma have been sold short.
Short Interest Ratio / Days to Cover
Cue Biopharma has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Cue Biopharma has recently increased by 1.23%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Cue Biopharma does not currently pay a dividend.
Dividend Growth
Cue Biopharma does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cue Biopharma has received a 74.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Cue Biopharma is -0.58.

2.3

News and Social Media Coverage

News Sentiment
Cue Biopharma has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Cue Biopharma this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for CUE on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.
MarketBeat Follows
3 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cue Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,620.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
10.24% of the stock of Cue Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 30.83% of the stock of Cue Biopharma is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cue Biopharma are expected to grow in the coming year, from ($1.22) to ($1.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cue Biopharma is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cue Biopharma is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cue Biopharma has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cue Biopharma (NASDAQ:CUE) Stock

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

CUE Price History

30 days | 90 days | 365 days | Advanced Chart

CUE Stock News Headlines

September 27, 2023 | finance.yahoo.com

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 26, 2023 | finanznachrichten.de

Cue Biopharma, Inc.: Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA

September 27, 2023 | Micro-Cap Stock Trader (Ad)

Windfall profits possible with this under-the-radar lithium stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 26, 2023 | finance.yahoo.com

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

August 30, 2023 | benzinga.com

Cue Biopharma And 2 Other Stocks Under $3 Insiders Are Buying

August 12, 2023 | finanznachrichten.de

Cue Biopharma, Inc.: Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 10, 2023 | msn.com

Cue Biopharma: Nothing Stands Out For This Cancer Immunotherapy Developer

August 10, 2023 | finance.yahoo.com

Investors in Cue Biopharma (NASDAQ:CUE) have unfortunately lost 83% over the last three years

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 10, 2023 | finance.yahoo.com

Cue Biopharma, Inc. (NASDAQ:CUE) Q2 2023 Earnings Call Transcript

August 10, 2023 | finance.yahoo.com

Q2 2023 Cue Biopharma Inc Earnings Call

August 10, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Buy Rating on Cue Biopharma (CUE)

August 9, 2023 | msn.com

Cue Biopharma GAAP EPS of -$0.29 beats by $0.01, revenue of $1.38M beats by $0.47M

August 9, 2023 | finance.yahoo.com

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 9, 2023 | finance.yahoo.com

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

August 1, 2023 | msn.com

Harmony Biosciences Holdings, Inc. (HRMY) Lags Q2 Earnings and Revenue Estimates

June 30, 2023 | finance.yahoo.com

3 Biotech Stocks to Buy as Companies Ink Major Deals

June 15, 2023 | markets.businessinsider.com

Where Cue Biopharma Stands With Analysts

June 15, 2023 | markets.businessinsider.com

Cue Biopharma (CUE) Receives a Buy from Piper Sandler

June 14, 2023 | finance.yahoo.com

Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

June 7, 2023 | finance.yahoo.com

Cue Biopharma to Host Investor Call

June 6, 2023 | markets.businessinsider.com

Piper Sandler Sticks to Its Buy Rating for Cue Biopharma (CUE)

June 5, 2023 | finance.yahoo.com

Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference

May 25, 2023 | finance.yahoo.com

Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 16, 2023 | msn.com

JMP Securities Reiterates Cue Biopharma (CUE) Outperform Recommendation

May 15, 2023 | finance.yahoo.com

Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 15, 2023 | markets.businessinsider.com

JMP Securities Sticks to Their Buy Rating for Cue Biopharma (CUE)

See More Headlines

Receive CUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter.

CUE Company Calendar

Last Earnings: 8/08/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CUE
CUSIP: N/A
CIK: 1645460
Web: www.cuebiopharma.com
Phone: (617) 949-2680
Fax: N/A
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.33
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +247.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-53,010,000.00
Net Margins: -2,899.44%
Pretax Margin: -2,899.39%
Return on Equity: -95.36%
Return on Assets: -64.32%

Debt

Debt-to-Equity Ratio: 0.13
Current Ratio: 3.74
Quick Ratio: 3.74

Sales & Book Value

Annual Sales: $1.25 million
Price / Sales: 86.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.53 per share
Price / Book: 1.57

Miscellaneous

Outstanding Shares: 44,960,000
Free Float: 40,356,000
Market Cap: $107.90 million
Optionable: Not Optionable
Beta: 2.02

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Daniel R. Passeri J.D. (Age 62)
M.Sc., MSc., CEO & Director
Comp: $985.72k

Dr. Anish Suri Ph.D. (Age 49)
Pres & Chief Scientific Officer
Comp: $641.98k

Ms. Kerri-Ann Millar (Age 53)
Chief Financial Officer
Comp: $559.03k

Dr. Ronald D. Seidel III (Age 47)
Ph.D., Co-Founder

Dr. Rodolfo J. Chaparro (Age 50)
Co-Founder & Sr. Advisor

Dr. Steven C. Almo (Age 62)
Co-Founder and Chairman of Scientific & Clinical Advisory Board

George B. Zavoico Ph.D.
VP of Investor Relations & Corp. Devel.

Mr. Colin G. Sandercock J.D. (Age 66)
MSE, Sr. VP, Gen. Counsel & Sec.

Dr. Matteo Levisetti M.D. (Age 54)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CUE Stock - Frequently Asked Questions

Should I buy or sell Cue Biopharma stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CUE shares.
View CUE analyst ratings or view top-rated stocks.
What is Cue Biopharma's stock price forecast for 2023?: 3 Wall Street analysts have issued 12-month price targets for Cue Biopharma's shares. Their CUE share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's share price to reach $8.33 in the next twelve months. This suggests a possible upside of 247.2% from the stock's current price.
View analysts price targets for CUE or view top-rated stocks among Wall Street analysts.
How have CUE shares performed in 2023?: Cue Biopharma's stock was trading at $2.85 at the beginning of 2023. Since then, CUE stock has decreased by 15.8% and is now trading at $2.40.
View the best growth stocks for 2023 here.
When is Cue Biopharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CUE earnings forecast.
How were Cue Biopharma's earnings last quarter?: Cue Biopharma, Inc. (NASDAQ:CUE) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.01. The company earned $1.38 million during the quarter, compared to analyst estimates of $1.21 million. Cue Biopharma had a negative trailing twelve-month return on equity of 95.36% and a negative net margin of 2,899.44%.
What other stocks do shareholders of Cue Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD).

What is Cue Biopharma's stock symbol?: Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."
Who are Cue Biopharma's major shareholders?: Cue Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.60%), Geode Capital Management LLC (1.62%), State Street Corp (1.45%), Dimensional Fund Advisors LP (1.29%), Silverarc Capital Management LLC (0.90%) and Monaco Asset Management SAM (0.86%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Cameron Gray, Daniel R Passeri, Kenneth Pienta, Kerri-Ann Millar and Peter A Kiener.
View institutional ownership trends.
How do I buy shares of Cue Biopharma?: Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cue Biopharma's stock price today?: One share of CUE stock can currently be purchased for approximately $2.40.
How much money does Cue Biopharma make?: Cue Biopharma (NASDAQ:CUE) has a market capitalization of $107.90 million and generates $1.25 million in revenue each year. The company earns $-53,010,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.
How can I contact Cue Biopharma?: Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.cuebiopharma.com. The company can be reached via phone at (617) 949-2680 or via email at ir@cuebio.com.

This page (NASDAQ:CUE) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cue Biopharma (CUE) Stock Forecast, Price & News

Cue Biopharma MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cue Biopharma (NASDAQ:CUE) Stock

CUE Price History

CUE Stock News Headlines

CUE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CUE Stock - Frequently Asked Questions

Overall MarketRank^™